公开(公告)号：US20220298197A1

公开(公告)日：2022-09-22

申请号：US17606134

申请日：2020-05-06

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  FIMBRION THERAPEUTICS, INC.

Inventor： Michael Joseph BISHOP ,  James Walter JANETKA ,  Laurel Kathryn MCGRANE ,  Eugene Lee STEWART ,  Katherine Louisa WIDDOWSON

IPC: C07H15/26 ,  C07H15/207

Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment diseases such as urinary tract infection.

公开(公告)号：US20220289859A1

公开(公告)日：2022-09-15

申请号：US17633115

申请日：2020-07-31

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： James K. Kranz ,  Michael Joseph Molloy ,  Joseph V. Rinella, Jr. ,  Elizabeth Rae Schmidt ,  Hillary Amber Schuessler ,  Tejash Shah

IPC: C07K16/28 ,  A61P35/00

Abstract: The invention described herein provides compositions comprising anti-BCMA antigen binding proteins and related methods for treating BCMA mediated diseases or disorders.

公开(公告)号：US11434032B2

公开(公告)日：2022-09-06

申请号：US16770981

申请日：2018-12-11

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： Francesco Sanmartin

IPC: B65B59/04 ,  A61L2/04 ,  B65B3/00 ,  B65B7/28 ,  B65B43/42 ,  B65B55/02

Abstract: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilize articles passing therethrough.

公开(公告)号：US20220257615A1

公开(公告)日：2022-08-18

申请号：US17619367

申请日：2020-07-03

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMIED

Inventor： Nicole SCANGARELLA-OMAN

IPC: A61K31/65 ,  A61K31/4985

Abstract: The present invention relates to methods for treating bacterial infections caused by or associated with Mycoplasma genitalium, which comprises administration of gepotidacin or pharmaceutically acceptable salts thereof, and doxycycline to a human in need thereof. Novel pharmaceutical combinations, compositions, resistance guided therapies and/or corresponding uses thereof are also disclosed.

公开(公告)号：US20220242900A1

公开(公告)日：2022-08-04

申请号：US17617642

申请日：2020-06-17

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  FIMBRION THERAPEUTICS, INC.

Inventor： Michael Joseph BISHOP ,  James Walter JANETKA ,  Laurel Kathryn MCGRANE ,  Katherine Louisa WIDDOWSON

IPC: C07H15/26 ,  C07H15/23

Abstract: Disclosed herein are new O-biphenyl- and O-phenylheteroarylmannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment of diseases such as urinary tract infection.

公开(公告)号：US20220218719A1

公开(公告)日：2022-07-14

申请号：US17610531

申请日：2020-05-15

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： Rachel APFELBAUM ,  Xin CHEN ,  Rennan PAN

IPC: A61K31/553 ,  A61K9/20 ,  A61P17/06

Abstract: The present invention relates to modified release pharmaceutical compositions of a RIP1 kinase inhibitor compound and forms thereof, processes or methods of composition preparation and uses or treatment methods therefor.

公开(公告)号：US11377440B2

公开(公告)日：2022-07-05

申请号：US16652221

申请日：2018-10-04

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： David T. Fosbenner ,  Todd L. Graybill ,  Jianxing Kang ,  Bryan W. King ,  Yunfeng Lan ,  Lara Kathryn Leister ,  Mukesh K. Mahajan ,  John F. Mehlmann ,  Angel I. Morales-Ramos ,  George Scott Pesiridis ,  Joshi M. Ramanjulu ,  Joseph J. Romano ,  Stuart Paul Romeril ,  Mark J. Schulz ,  Huiqiang Zhou ,  Junya Qu

IPC: C07D403/14 ,  C07D401/14 ,  C07D405/14

Abstract: Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

公开(公告)号：US11365190B2

公开(公告)日：2022-06-21

申请号：US17156893

申请日：2021-01-25

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： Adam Kenneth Charnley ,  Gren Z. Wang ,  Joseph J. Romano

IPC: C07D413/14 ,  C07D403/14 ,  C07D405/14 ,  C07D487/22 ,  C07D493/10 ,  C07D498/18 ,  C07F9/6558

Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

公开(公告)号：US20220168417A1

公开(公告)日：2022-06-02

申请号：US17602434

申请日：2020-04-09

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  SPRINGWORKS THERAPEUTICS, INC.

Inventor： Swethajit BISWAS ,  Beata HOLKOVA ,  Katarina LUPTAKOVA

IPC: A61K39/395 ,  A61K31/417 ,  A61P35/00

Abstract: The disclosure concerns a method of treating cancer, especially, such as multiple myeloma, involving the combination of an anti-BCMA (B cell maturation antigen) antibody, Belantamab mafodotin -GSK2857916- and a gamma-secretase inhibitor, e.g., nirogacestat -PF03084014-. The disclosure also relates to dosages, duration of treatment and time lapses between administration of the anti-BCMA antibody and the gamma-secretase inhibitor.

公开(公告)号：US20220112174A1

公开(公告)日：2022-04-14

申请号：US17492978

申请日：2021-10-04

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Edward BRNARDIC ,  Michael BURY ,  Rodolfo CADILLA ,  Jon COLLINS ,  Yu GUO ,  Anthony HANDLON ,  Huijie LI ,  Yue LI ,  Daniel PAONE ,  Christie SCHULTE ,  Barry SHEARER ,  Guosen YE ,  Maben YING ,  Huichang ZHANG

IPC: C07D401/14

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.